NCT02048813 · OUTCOME

Prognostic Model to Predict PFS

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Source last updated 2026-08-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5

What was measured

A prognostic model that incorporates clinical and biologic characters to predict PFS will be developed.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: A prognostic model that incorporates clinical and biologic characters to predict PFS will be developed.
reporting Status: NOT_POSTED
time Frame: Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5
title: Prognostic Model to Predict PFS
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice